Yonsei Med J.  2017 Sep;58(5):1055-1060. 10.3349/ymj.2017.58.5.1055.

Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea

• Lee KH
• Seo SW
• Lim TS
• Kim EJ
• Kim BC
• Kim Y
• Lee HW
• Jeon JP
• Shim SM
• Na DL
• Huh GY
• Lee MC
• Suh YL

• KMID: 2418946
• DOI: http://doi.org/10.3349/ymj.2017.58.5.1055

Abstract

To obtain an in-depth understanding of brain diseases, including neurodegenerative diseases, psychiatric illnesses, and neoplasms, scientific approach and verification using postmortem human brain tissue with or without disease are essential. Compared to other countries that have run brain banks for decades, South Korea has limited experience with brain banking; nationwide brain banks started only recently. The goal of this study is to provide provisional guidelines for brain autopsy for hospitals and institutes that have not accumulated sufficient expertise. We hope that these provisional guidelines will serve as a useful reference for pathologists and clinicians who are involved and interested in the brain bank system. Also, we anticipate updating the provisional guidelines in the future based on collected data and further experience with the practice of brain autopsy in South Korea.

Keyword

Dementia; neuropathology; guideline; standardization

MeSH Terms

Autopsy/*standards
Brain/*pathology
Dissection
*Guidelines as Topic
Humans
Immunohistochemistry
Republic of Korea
*Tissue Banks

Figure

• 

  Fig. 1 Illustration showing where to collect the core and additional blocks listed in Table 1.

Reference

1. Bigio EH. Making the diagnosis of frontotemporal lobar degeneration. Arch Pathol Lab Med. 2013; 137:314–325.

2. Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol. 2008; 115:509–532.

3. Ross BM, Knowler JT, McCulloch J. On the stability of messenger RNA and ribosomal RNA in the brains of control human subjects and patients with Alzheimer's disease. J Neurochem. 1992; 58:1810–1819.

4. Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC. Gene expression profiling in the post-mortem human brain--no cause for dismay. J Chem Neuroanat. 2001; 22:79–94.

5. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012; 8:1–13.

6. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012; 123:1–11.

7. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997; 56:1095–1097.

8. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58:1791–1800.

9. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000; 59:733–748.

10. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112:389–404.

11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82:239–259.

12. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41:479–486.

13. Lowe J, Kalaria R. Dementia. In : Love S, Perry A, Ironside J, Budka H, editors. Greenfield's neuropathology. 9th ed. London: CRC Press;2015. p. 858–973.

14. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65:1863–1872.

15. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006; 65:685–697.

16. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010; 119:1–4.

17. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011; 122:111–113.

18. Montine TJ, Larson EB. Late-life dementias: does this unyielding global challenge require a broader view. JAMA. 2009; 302:2593–2594.

19. Glasel JA. Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. Biotechniques. 1995; 18:62–63.

20. Barbas CF 3rd, Burton DR, Scott JK, Silverman GJ. Quantitation of DNA and RNA. CSH Protoc. 2007; 2007:pdb.ip47.

21. Mueller O, Lightfoot S, Schroeder A. RNA integrity number (RIN)-standardization of RNA quality control. accessed on 2006 January 31. Available at: http://gene-quantification.net/RIN.pdf.